{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n The term “BMT2” appears in these studies in two very different contexts. In several hematologic investigations, “BMT2” designates a second allogeneic bone marrow transplant administered to patients after the failure, rejection, or relapse following their first transplant (BMT1). These reports show that a well‐timed BMT2—often influenced by parameters such as the interval between transplants, patient age, donor matching, and conditioning regimens—can restore engraftment and improve long‐term survival in selected patients."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "4"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In a very different arena, “Bmt2” refers to a methyltransferase enzyme identified during ribosome biogenesis. In this setting, Bmt2 catalyzes specific methylation reactions on ribosomal RNA intermediates during the assembly of the 60S subunit—an essential post‐transcriptional modification that helps ensure the proper formation and function of ribosomes."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Together, these findings highlight that while “BMT2” as a clinical procedure functions to salvage hematopoiesis in patients with prior transplant complications, Bmt2 the enzyme plays a critical role in fine‐tuning ribosome assembly via rRNA methylation. Despite sharing the same abbreviation, the “functions” of BMT2 in these contexts underscore the diversity of biomedical processes—from life‐saving therapeutic interventions to the regulation of fundamental cellular machineries.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "F Al-Qurashi, M Ayas, F Al Sharif, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hematology (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1080/10245330310001652509"}], "href": "https://doi.org/10.1080/10245330310001652509"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15203867"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15203867"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "C R de Medeiros, M A Bitencourt, B C Medeiros, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Second bone marrow transplantation for severe aplastic anemia: analysis of 34 cases."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Bone Marrow Transplant (2001)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.bmt.1703257"}], "href": "https://doi.org/10.1038/sj.bmt.1703257"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11753548"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11753548"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "D Gaziev, P Polchi, G Lucarelli, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Second marrow transplants for graft failure in patients with thalassemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Bone Marrow Transplant (1999)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.bmt.1702076"}], "href": "https://doi.org/10.1038/sj.bmt.1702076"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "10627638"}], "href": "https://pubmed.ncbi.nlm.nih.gov/10627638"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "K Kishi, S Takahashi, H Gondo, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Bone Marrow Transplant (1997)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.bmt.1700680"}], "href": "https://doi.org/10.1038/sj.bmt.1700680"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "9052912"}], "href": "https://pubmed.ncbi.nlm.nih.gov/9052912"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Carolin Sailer, Jasmin Jansen, Kamil Sekulski, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A comprehensive landscape of 60S ribosome biogenesis factors."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Rep (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.celrep.2022.110353"}], "href": "https://doi.org/10.1016/j.celrep.2022.110353"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35139378"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35139378"}]}]}]}